PN-943
An oral gut-restricted peptide antagonist of alpha4beta7 integrin studied in ulcerative colitis.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Investigational
Investigational; not FDA-approved for the uses discussed.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An oral gut-restricted peptide antagonist of alpha4beta7 integrin studied in ulcerative colitis.
Investigational; not FDA-approved for the uses discussed.
Active 2026 registrational development was not verified; an earlier phase 3 intention is not evidence that such a trial started.
Why It's Being Studied
- Ulcerative colitis
- Intestinal immune trafficking
Mechanism of Action
It is intended to reduce trafficking of lymphocytes into inflamed intestinal tissue.
It is intended to reduce trafficking of lymphocytes into inflamed intestinal tissue. Active 2026 registrational development was not verified; an earlier phase 3 intention is not evidence that such a trial started.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Ulcerative colitis
- Intestinal immune trafficking
- Oral clinical research
Evidence Summary
Phase 2 IDEAL reported remission signals in a lower-dose arm, with dose-response and primary-analysis limitations.
Higher tiers carry more weight. Filled tiers have evidence for PN-943; tap to read it.
- Phase 2 IDEAL reported remission signals in a lower-dose arm, with dose-response and primary-analysis limitations.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Phase 2 IDEAL reported remission signals in a lower-dose arm, with dose-response and primary-analysis limitations.
Reported Adverse Events in Research
- Small and indication-specific trials do not define long-term immune or infection risks.
Limitations of Current Evidence
- Active 2026 registrational development was not verified; an earlier phase 3 intention is not evidence that such a trial started.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| PN-943 | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Investigational | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Oral clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
PN-943 — regulatory document